Primary Pulmonary Hypertension (PAH) — Classic Drug Formulations

3 Pathways, 3 Drug Classes:

Key One-Liners:

1. Epoprostenol (IV prostacyclin) = only drug proven to improve survival in PAH; drug of choice in WHO FC IV.
2. Bosentan = first oral ERA approved; blocks both ET-A and ET-B receptors → vasodilation + antiproliferative.
3. Sildenafil = PDE-5 inhibitor → ↑ cGMP → pulmonary vasodilation (same mechanism as in erectile dysfunction).
4. Riociguat = uniquely approved for both PAH and CTEPH (only drug with dual approval).
5. Combination therapy (ERA + PDE-5i, e.g., ambrisentan + tadalafil) = current standard for most newly diagnosed PAH patients.

Plexiform Lesions in Primary Pulmonary Hypertension

1. What they are: Tufts of disorganized capillary formations (network/web) that span and occlude the lumens of small, dilated pulmonary arteries (40–300 µm diameter) — the pathognomonic end-stage vascular lesion of advanced PAH. They represent neointimal proliferation of endothelial cells in a disordered, angioma-like pattern (monoclonal endothelial proliferation in IPAH).
2. Key associations (most prominent in):
   • Idiopathic & familial PAH (Group 1) ← classic exam answer
   • Unrepaired congenital heart disease with left-to-right shunts (Eisenmenger)
   • HIV-associated PAH and drug-induced PAH

One-liner: Plexiform lesion = web-like tuft of capillaries obliterating small pulmonary artery lumen = hallmark of irreversible, advanced PAH (Heath-Edwards Grade IV–VI).

ARDS: Diffuse Alveolar Damage (DAD) — The Core Mechanism

Step-by-Step Cascade:

• The alveolar-capillary unit = type I pneumocytes (lining alveoli) + capillary endothelial cells (carrying blood), separated by a thin basement membrane.
• In ARDS, a massive inflammatory insult (sepsis, aspiration, trauma, etc.) activates neutrophils → they release elastases, reactive oxygen species (ROS), matrix metalloproteinases (MMPs) → these destroy both the endothelial and epithelial cell layers.
• Result: the normally tight barrier is blown open.

• Normally, capillaries are tight — only water and small solutes cross.
• Once endothelium is injured → intercellular junctions widen → plasma proteins (albumin, fibrin, fibrinogen) flood into the alveolar interstitium and airspaces.
• This is non-cardiogenic pulmonary edema — flooding WITHOUT raised left heart pressures (key distinction from cardiogenic edema).

• Type I pneumocytes (cover 95% of alveolar surface) are extensively necrotic → alveolar lining is denuded (stripped bare to the basement membrane).
• Type II pneumocytes (surfactant producers) are also injured → surfactant is lost/inactivated by the flooded protein-rich fluid → alveoli collapse (atelectasis).

• The leaked plasma proteins (fibrin + plasma) + debris from necrotic type I pneumocytes condense and precipitate on the denuded basement membrane.
• This forms hyaline membranes — eosinophilic, glassy, homogeneous deposits lining the alveolar walls.
• "Hyaline" = glassy appearance on H&E staining.
• They physically coat the alveoli, drastically reducing gas exchange surface area.

• Alveoli are: flooded with edema + collapsed (no surfactant) + lined by hyaline membranes.
• Massive intrapulmonary shunt (blood perfuses unventilated alveoli) → refractory hypoxemia (PaO₂/FiO₂ < 300 mmHg) that does NOT improve with supplemental O₂ alone.
• This pathologic picture = Diffuse Alveolar Damage (DAD) = the histologic correlate of clinical ARDS.

Ultra One-Liner:

Inflammatory injury → endothelial + epithelial destruction → protein-rich flood into alveoli + type I pneumocyte necrosis → fibrin + cellular debris condense on bare basement membrane = hyaline membranes → alveolar flooding + collapse + diffuse shunting = ARDS.

Stem Cell of the Lung Alveolus = Type II Pneumocyte

• After injury (e.g., ARDS, toxic damage), Type II cells proliferate and differentiate into Type I pneumocytes to regenerate the alveolar lining.
• This is why in the organizing/proliferative phase of DAD (after the acute exudative phase), you see Type II pneumocyte hyperplasia lining the alveoli — it's the repair response.

One-liner memory hook:

Type I = gas exchange (thin, flat, covers 95% surface) — fragile, can't regenerate itself Type II = surfactant producer + stem cell → replenishes Type I after injury

Surfactant & Surface Tension — The Simple Concept

Dead Simple Analogy:

Imagine trying to blow up a wet balloon — it keeps collapsing. Spray it with soap (surfactant) → it opens easily and stays open. That's exactly what surfactant does for alveoli.

Why it matters clinically:

• Premature babies lack surfactant → Neonatal Respiratory Distress Syndrome (NRDS) → lungs collapse → treated with exogenous surfactant.
• In ARDS, protein-rich edema inactivates surfactant → same collapse problem in adults.

Surface Tension — The Core Concept

The Result:

This is why a water droplet forms a sphere — a sphere has the smallest surface area for its volume. The water is literally squeezing itself into the tightest shape possible.

This is why small insects can walk on water — the surface film is strong enough to support them.

Now apply this to the alveolus:

One sentence:

Surface tension = water molecules at the air-water interface have an unbalanced inward pull → the surface contracts → in the lung, this collapses alveoli → surfactant disrupts this pull and keeps them open.

Surface Area vs Volume — Explained to a 10-Year-Old

First, what are they?

Now, why does a sphere have the LEAST surface area for its volume?

• A long thin snake 🐍 — tons of surface, tiny volume
• A flat pancake 🥞 — lots of surface, tiny volume
• A ball/sphere 🔵 — the least surface for that same amount of clay

Simple analogy:

• If you make a flat slab, the candy barely fits and lots of Play-Doh is exposed.
• If you roll it into a ball, you use the least Play-Doh to wrap the same amount of candy.

Why does nature love spheres?

One line: Volume = space inside. Surface area = skin outside. A sphere fits the most inside with the least outside — so surface tension always pulls water into a sphere.